- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Canon's Cartesion Prime is a Digital PET/CT Solution Fit for the Times
Canon's latest entry into the PET/CT market is a digital, air-cooled system that provides customizable solutions for a range of clients.
As the country--and the world--continues to grapple with the ongoing COVID pandemic, the imaging industry is looking to re-find its footing in an evolving landscape where customized solutions are key to success.
Enter Canon Medical's Cartesion Prime digital PET/CT, introduced in 2019, which provides a high-performance, adaptable system for today's evolving imaging technology. Optimizing both workflow and image quality via advanced silicon photomultiplier design with one-to-one coupling, fast time-of-flight and deep learning reconstruction technology, “this advanced technology has led to image quality improvements, while optimizing dose efficiency to reduce patient risk and speeding up acquisition time for improved throughput," said Tim Nicholson, managing director, Molecular Imaging Business Unit, Canon Medical Systems USA.
In an interview with Diagnostic Imaging, Nicholson expanded on the needs of the industry and how Canon is answering the call.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
